JOHNSON & JOHNSON (JNJ)
US4781601046 - Common Stock
Neuropathic Pain Market Set to Witness Significant Growth by 2024-2031 | Pfizer, Inc., Johnson & Johnson Services
Global Neuropathic Pain Market is estimated to valued at US$ 7.56 Billion in 2023 and expected to exhibit a CAGR of 6.2% during the forecast period 2023-2030
The Smartest Dividend Stocks to Buy With $500 Right Now
The Smartest Dividend Stocks to Buy With $500 Right Now
If you add a few dividend stocks to your portfolio, you'll start collecting returns on a regular basis -- without lifting a finger. Loads of companies pay dividends, so it might seem difficult make a selection. A great way to start is to consider the list of Dividend Kings, companies that have increased their dividend payments for at least 50 consecutive years.
Johnson & Johnson (JNJ) Stock Declines While Market Improves: Some Information for Investors
In the most recent trading session, Johnson & Johnson (JNJ) closed at $143.85, indicating a -1.89% shift from the previous trading day.
J&J accuses divisions of Cigna of helping drain its drug copay funds, WSJ reports
Johnson & Johnson has sued divisions of Cigna, accusing the health insurer of working with a drug-benefit middleman to drain J&J's financial-assistance funds earmarked for patients taking some of its pricier drugs, The Wall Street Journal reported on Friday.
Friday 12/13 Insider Buying Report: PLAY, JNJ
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
Johnson & Johnson to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
These Are the 5 Worst-Performing Stocks in the Dow Jones Industrial Average With 2024 Almost Over
Unsupported price hikes added $815 million to US drug spending in 2023
Price increases for five of the 10 drugs that contributed the most to a rise in U.S. medical spending in 2023 were not supported by clinical evidence and drove costs higher by $815 million, an influential drug pricing watchdog said on Thursday. The Institute for Clinical and Economic Review (ICER) said that half of the drugs assessed had price increases based on new evidence of additional benefits or reduced harm, while the other half lacked such evidence. Johnson & Johnson's cancer drug Darzalex was on the list of price increases not backed by clinical evidence for the second time this year.
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results
CARVYKTI® (ciltacabtagene autoleucel) demonstrated significantly higher rates of minimal residual disease (MRD) negativity compared to standard therapies in the CARTITUDE-4 study
/PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today new results from the Phase 3 CARTITUDE-4 study that show a single infusion of CARVYKTI®...
GSK Cancer Drug Poised for Comeback After Lifting Survival Rates
A GSK Plc drug dramatically cut the risk of dying from an incurable blood cancer in a study, suggesting that the medicine withdrawn two years ago could return to market and become a blockbuster.
Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.
The companies held competing events on Sunday to discuss their multiple myeloma treatments.
Warm autoimmune hemolytic anemia (wAIHA) research presented by Johnson & Johnson highlights profound disease burden and unmet need for targeted treatment options
Abstracts presented at ASH 2024 provide insight into the patient experience given the unpredictable nature of wAIHA, a rare autoantibody disease, and the...
Why NYSE:JNJ is a Top Pick for Dividend Investors.
Exploring JOHNSON & JOHNSON (NYSE:JNJ)'s dividend characteristics.
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimens demonstrate improved rates of minimal residual disease (MRD) negativity and progression-free survival in patients with newly diagnosed multiple myeloma
/PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced data highlighting that DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimens...
TECVAYLI® (teclistamab-cqyv) demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myeloma
/PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new frontline data featuring TECVAYLI® (teclistamab-cqyv) from two investigational studies in...
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) shows 51 percent reduction in risk of progression to active multiple myeloma for patients with high-risk smoldering multiple myeloma
/PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced data from the Phase 3 AQUILA study showing that DARZALEX FASPRO® (daratumumab and...
Coca-Cola cs. Procter & Gamble: Which Is the Better Dow Dividend King Stock to Buy Before the End of the Year?
The Zacks Analyst Blog Highlights Home Depot, Johnson & Johnson, Salesforce, Preformed Line and Cooper-Standard
Home Depot, Johnson & Johnson, Salesforce, Preformed Line and Cooper-Standard are included in this Analyst Blog.
Johnson & Johnson Enters Oversold Territory
making Johnson & Johnson an even more interesting and timely stock to look at, is the fact that in trading on Friday, shares of JNJ entered into oversold territory
Top Analyst Reports for Home Depot, Johnson & Johnson & Salesforce
Today's Research Daily features new research reports on 16 major stocks, including The Home Depot, Inc. (HD), Johnson & Johnson (JNJ) and Salesforce, Inc. (CRM), as well as two micro-cap stocks, Preformed Line Products Company (PLPC) and Cooper-Standard Holdings Inc. (CPS).